Clinical trials: Non Therapeutic Body Modification
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
The purpose of this clinical research trial is to study safety and effectiveness of the TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered medically obese.
- Trial name
- NCT02518685
- Testing
- TransPyloric Shuttle, Lifestyle Counseling
- Where
- 9 sites in United States
- Volunteers
- 302 people
- Sponsor
- BaroNova, Inc.
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Non Therapeutic Body Modification
Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI
Approximately 165 subjects with Fitzpatrick Skin Color Types IV, V, and VI and a moderate to deep wrinkle between the corner of the nose and the corner of the mouth, will be treated with EVOLENCE® (an approved collagen filler) to…
- Trial name
- NCT00891774
- Testing
- EVOLENCE®
- Where
- 11 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Obesity
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss.
- Trial name
- NCT03779048
- Testing
- Behavioral Treatment, Phentermine 15 MG
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University of Pennsylvania
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Loss-of-control Eating, Obesity/Overweight
Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
This study will test the effectiveness of lisdexamfetamine medication as a treatment for loss-of-control eating and weight following bariatric surgery.
- Trial name
- NCT04599504
- Testing
- Lisdexamfetamine Dimesylate (Medication)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Yale University
Lymphoma
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00039195
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cachexia; Cancer, Non Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia…
- Trial name
- NCT03743064
- Testing
- anamorelin HCl
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 318 people
- Sponsor
- Helsinn Healthcare SA
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
Cachexia, Non-Small Cell Lung Cancer
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01395914
- Testing
- Anamorelin HCl
- Where
- 72 sites in United States, Australia and 15 more
- Volunteers
- 513 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Cachexia
Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioning and increased nutrition is not…
- Trial name
- VT-122 (NCT00527319)
- Testing
- VT-122 low dose, VT-122 high dose
- Where
- 8 sites in United States, India
- Volunteers
- 37 people
- Sponsor
- Vicus Therapeutics
Leukemia, Lymphoma
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional…
- Conditions
- Leukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes
- Trial name
- NCT00949117
- Testing
- Ensure, PediaSure, cyproheptadine hydrochloride
- Volunteers
- 9 people
- Sponsor
- University of South Florida
Cachexia; Cancer, Non Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia…
- Trial name
- NCT03743051
- Testing
- Anamorelin Hydrochloride
- Where
- 72 sites in United States, Bulgaria and 5 more
- Volunteers
- 318 people
- Sponsor
- Helsinn Healthcare SA
Binge-Eating Disorder, Obesity
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity.
- Trial name
- NCT03946111
- Testing
- Naltrexone and Bupropion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Lymphocyte Depletion
Lymphocyte Depletion and Change in Lymphocyte Functionality
Lymphocytes are a type of white blood cell (WBC) responsible for adaptive immunity. Thoracic tumors are adjacent to many blood/immune rich organs including the great vessels, heart, thoracic-spine, and lymph-node-stations.
- Trial name
- NCT04273893
- Testing
- SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Virginia
Non-Therapeutic Body Modification
EMS for Abdominal and Gluteal Muscle Toning
Evaluate the use of Electromagnetic Muscle Stimulation for body contouring.
- Trial name
- CTP (NCT03983304)
- Testing
- The ZELTIQ EMS System
- Where
- 8 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Lung Cancer, Malnutrition
Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer
This is a two-part study. Part I is an observational study. Part II is a randomized clinical trial to see how well medical nutrition therapy works compared with standard care in treating patients with lung cancer, pancreatic…
- Conditions
- Lung Cancer, Malnutrition, Pancreatic Cancer, Prostate Cancer
- Trial name
- NCT00769652
- Testing
- Medical nutrition therapy, Standard Care
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rutgers, The State University of New Jersey
Obesity, Overweight
Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals
Background: Sticking to a diet plan can be difficult, but is important for many different health reasons. Some people seem to have a harder time following and sticking to a diet plan than others.
- Trial name
- NCT01862796
- Testing
- Underfeeding diet, Weight maintaining diet
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387269
- Testing
- Anamorelin HCl
- Where
- 60 sites in United States, Belarus and 14 more
- Volunteers
- 484 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc